Terms: = Germ cell tumor AND PBRM1, BAF180, 55193, PB1, MGC156156, MGC156155 AND Treatment
5 results:
1. The immune response-related genomic alterations in patients with malignant melanoma.
Li L; Xiang T; Li X
Medicine (Baltimore); 2024 Apr; 103(17):e37966. PubMed ID: 38669390
[TBL] [Abstract] [Full Text] [Related]
2. The mutational landscape of skull base and spinal chordomas and the identification of potential prognostic and theranostic biomarkers.
Passeri T; Gutman T; Hamza A; Adle-Biassette H; Girard E; Beaurepere R; Tariq Z; Mariani O; Dahmani A; Bourneix C; Abbritti R; Driouch K; Bohec M; Servant N; Baulande S; Decaudin D; Guichard JP; Calugaru V; Feuvret L; Guinebretière JM; Champion L; Bièche I; Froelich S; Mammar H; Masliah-Planchon J
J Neurosurg; 2023 Nov; 139(5):1270-1280. PubMed ID: 37029667
[TBL] [Abstract] [Full Text] [Related]
3. Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes.
Bai J; Shi J; Zhang Y; Li C; Xiong Y; Koka H; Wang D; Zhang T; Song L; Luo W; Zhu B; Hicks B; Hutchinson A; Kirk E; Troester MA; Li M; Shen Y; Ma T; Wang J; Liu X; Wang S; Gui S; McMaster ML; Chanock SJ; Parry DM; Goldstein AM; Yang XR
Clin Cancer Res; 2023 Jan; 29(1):261-270. PubMed ID: 36260525
[TBL] [Abstract] [Full Text] [Related]
4. ARID2 Deficiency Correlates with the Response to Immune Checkpoint Blockade in Melanoma.
Fukumoto T; Lin J; Fatkhutdinov N; Liu P; Somasundaram R; Herlyn M; Zhang R; Nishigori C
J Invest Dermatol; 2021 Jun; 141(6):1564-1572.e4. PubMed ID: 33333124
[TBL] [Abstract] [Full Text] [Related]
5. A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing.
Pan D; Kobayashi A; Jiang P; Ferrari de Andrade L; Tay RE; Luoma AM; Tsoucas D; Qiu X; Lim K; Rao P; Long HW; Yuan GC; Doench J; Brown M; Liu XS; Wucherpfennig KW
Science; 2018 Feb; 359(6377):770-775. PubMed ID: 29301958
[TBL] [Abstract] [Full Text] [Related]
